The company said it held its 2026 Investor Day in Mesa, Arizona, on May 14, 2026, discussing market opportunities, business strategy, innovation efforts and long-term financial outlook. It also posted an investor presentation and a replay of the webcast on its investor relations website.

1. 01

   The company said it held its 2026 Investor Day in Mesa, Arizona, on May 14, 2026, discussing market opportunities, business strategy, innovation efforts and long-term financial outlook. It also posted an investor presentation and a replay of the webcast on its investor relations website.

2. 02

   Dexcom set new long-range targets through 2030: Organic Revenue growth of 10%+ every year, Non-GAAP Gross Profit Margin of 67-69% in 2030, Non-GAAP Operating Profit Margin of 29-30%, and Adjusted EBITDA Margin of 36-37%.

3. 03

   The company said its Board of Directors approved a share repurchase program of up to $1.0 billion of common stock on May 14, 2026, with the repurchase period ending no later than June 30, 2027. The Board terminated the existing program, under which $250.0 million remained available for repurchase.

4. 04

   The company said it may repurchase shares in the open market, in privately negotiated transactions or through Rule 10b5-1 trading plans, at its discretion. It said it is not obligated to repurchase any specific dollar amount or number of shares, and the program may be extended, modified, suspended or discontinued at any time.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.